Skip to main content
RCUS logo

RCUS

Arcus Biosciences, Inc.

$27.37

2.75%

Trade Ideas Performance

Latest Closed Trade Idea

$27.37

2.75%
Loading...
We are loading your data. Please wait a moment.

Sentiment

News

1

Social

20

About

Events of Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences reported Q1 2026 revenue of $17 million, a decrease from $28 million in Q1 2025, with a net loss widening to $128 million. Arcus Biosciences and Gilead Sciences discontinued the Phase 3 STAR-121 and Phase 2 EDGE-Lung studies due to futility. Gilead Sciences announced it would let certain option rights lapse in July 2026, narrowing its access to Arcus's early pipeline. Arcus has emphasized its strategic realignment around casdatifan, aiming to establish it as a foundational standard of care in kidney cancer. Analysts have maintained a "Buy" consensus for RCUS, with a mean price target of $34.

Read more

FAQ

Related Assets

Price action provided by Massive. Fundamentals, news and corporate events provided by FactSet. NLP support provided by Perplexity & Gemini. All data is provided for informational purposes only.

Make every trade make sense.

Sign up free. No card required. Three trade ideas a day, the AI analyst, the community - on us.

Get started for FREE (opens in new tab)
Edge Hound mobile app preview on iPhone

Join us and trade with people
who think like you.

The Edge Hound Discord is where serious self-directed investors talk strategy, share setups, and learn from each other. Free to join with any plan - including Free.

Free to join with any plan - including Free.

Join our Discord community (opens in new tab)
Arcus Biosciences, Inc. (RCUS) Live Stock Price, Chart & Financial News | Edge Hound